Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1948 5
1949 3
1950 1
1951 3
1952 5
1953 4
1954 1
1955 4
1956 3
1957 2
1958 1
1959 1
1960 1
1961 1
1962 2
1966 1
1968 2
1972 1
1973 1
1974 2
1975 1
1976 1
1977 1
1979 1
1980 1
1981 2
1982 8
1983 6
1984 7
1985 5
1986 13
1987 9
1988 8
1989 10
1990 16
1991 12
1992 15
1993 12
1994 18
1995 30
1996 26
1997 22
1998 15
1999 35
2000 31
2001 35
2002 40
2003 28
2004 35
2005 48
2006 51
2007 41
2008 46
2009 42
2010 58
2011 73
2012 73
2013 91
2014 88
2015 79
2016 98
2017 98
2018 121
2019 106
2020 115
2021 126
2022 114
2023 108
2024 105

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,929 results

Results by year

Filters applied: . Clear all
Page 1
RpoS and the bacterial general stress response.
Bouillet S, Bauer TS, Gottesman S. Bouillet S, et al. Among authors: bauer ts. Microbiol Mol Biol Rev. 2024 Mar 27;88(1):e0015122. doi: 10.1128/mmbr.00151-22. Epub 2024 Feb 27. Microbiol Mol Biol Rev. 2024. PMID: 38411096 Review.
A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G, Mazieres J, Stratmann J, Ou SI, Mok T, Grizzard M, Goto Y, Felip E, Solomon BJ, Bauer TM. Liu G, et al. Among authors: bauer tm. Lung Cancer. 2024 May;191:107535. doi: 10.1016/j.lungcan.2024.107535. Epub 2024 Mar 15. Lung Cancer. 2024. PMID: 38554546 Free article. Review.
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, Davenport T, Teufel M, Li J, Lahmar M, Gounder MM. LoRusso P, et al. Among authors: bauer tm. Cancer Discov. 2023 Aug 4;13(8):1802-1813. doi: 10.1158/2159-8290.CD-23-0153. Cancer Discov. 2023. PMID: 37269344 Free PMC article. Clinical Trial.
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Solomon BJ, et al. Among authors: bauer tm. J Clin Oncol. 2022 Nov 1;40(31):3593-3602. doi: 10.1200/JCO.21.02278. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605188 Free PMC article. Clinical Trial.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Shaw AT, et al. Among authors: bauer tm. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. Shaw AT, et al. Among authors: bauer tm. J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892989 Free PMC article. Clinical Trial.
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Felip E, et al. Among authors: bauer tm. Ann Oncol. 2021 May;32(5):620-630. doi: 10.1016/j.annonc.2021.02.012. Epub 2021 Feb 24. Ann Oncol. 2021. PMID: 33639216 Free article. Clinical Trial.
Multicenter evaluation of the BIOFIRE Joint Infection Panel for the detection of bacteria, yeast, and AMR genes in synovial fluid samples.
Esteban J, Salar-Vidal L, Schmitt BH, Waggoner A, Laurent F, Abad L, Bauer TW, Mazariegos I, Balada-Llasat J-M, Horn J, Wolk DM, Jefferis A, Hermans M, Verhoofstad I, Butler-Wu SM, Umali-Wilcox M, Murphy C, Cabrera B, Craft D, von Bredow B, Leber A, Everhart K, Dien Bard J, Flores II, Daly J, Barr R, Holmberg K, Graue C, Kensinger B. Esteban J, et al. Among authors: bauer tw. J Clin Microbiol. 2023 Nov 21;61(11):e0035723. doi: 10.1128/jcm.00357-23. Epub 2023 Oct 25. J Clin Microbiol. 2023. PMID: 37877730 Free PMC article.
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. Strickler JH, et al. Among authors: bauer tm. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. J Clin Oncol. 2018. PMID: 30285518 Clinical Trial.
1,929 results